Regulus Therapeutics Stock Revenue
| RGLS Stock | USD 1.63 0.02 1.24% |
Regulus Therapeutics fundamentals help investors to digest information that contributes to Regulus Therapeutics' financial success or failures. It also enables traders to predict the movement of Regulus Stock. The fundamental analysis module provides a way to measure Regulus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Regulus Therapeutics stock.
| Last Reported | Projected for Next Year |
Regulus | Revenue |
Regulus Therapeutics Company Revenue Analysis
Regulus Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Regulus
Projected quarterly revenue analysis of Regulus Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Regulus Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Regulus Therapeutics' stock price.
Regulus Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Regulus Therapeutics is extremely important. It helps to project a fair market value of Regulus Stock properly, considering its historical fundamentals such as Revenue. Since Regulus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Regulus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Regulus Therapeutics' interrelated accounts and indicators.
| 0.56 | -0.05 | -0.18 | 0.72 | 0.19 | ||
| 0.56 | 0.17 | -0.28 | 0.28 | 0.37 | ||
| -0.05 | 0.17 | 0.46 | -0.12 | -0.38 | ||
| -0.18 | -0.28 | 0.46 | -0.1 | -0.84 | ||
| 0.72 | 0.28 | -0.12 | -0.1 | 0.16 | ||
| 0.19 | 0.37 | -0.38 | -0.84 | 0.16 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Regulus Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Regulus Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Regulus Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regulus Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Regulus Therapeutics could also be used in its relative valuation, which is a method of valuing Regulus Therapeutics by comparing valuation metrics of similar companies.Regulus Therapeutics is currently under evaluation in revenue category among its peers.
Regulus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Regulus Therapeutics from analyzing Regulus Therapeutics' financial statements. These drivers represent accounts that assess Regulus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Regulus Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 15.4M | 47.2M | 27.4M | 20.9M | 24.0M | 22.8M | |
| Enterprise Value | (4.1M) | 20.8M | (25.9M) | 3.0M | 3.4M | 3.2M |
Regulus Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Regulus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Regulus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Regulus Therapeutics' value.| Shares | Alyeska Investment Group, L.p. | 2024-09-30 | 1 M | State Street Corp | 2024-09-30 | 1 M | Woodline Partners Lp | 2024-09-30 | 948.7 K | Dafna Capital Management Llc | 2024-09-30 | 895.2 K | Point72 Asset Management, L.p. | 2024-09-30 | 893.8 K | Ra Capital Management, Llc | 2024-09-30 | 766.8 K | Opaleye Management Inc | 2024-09-30 | 535 K | Northern Trust Corp | 2024-09-30 | 497.3 K | Cvi Holdings Llc | 2024-06-30 | 401 K | Federated Hermes Inc | 2024-09-30 | 12.9 M | Nea Management Company, Llc | 2024-09-30 | 6.5 M |
Regulus Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Current Valuation | 18.63 M | ||||
| Shares Outstanding | 65.5 M | ||||
| Shares Owned By Insiders | 1.69 % | ||||
| Shares Owned By Institutions | 88.29 % | ||||
| Number Of Shares Shorted | 1.64 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 7.43 X | ||||
| Gross Profit | (18.41 M) | ||||
| EBITDA | (30.88 M) | ||||
| Net Income | (30.04 M) | ||||
| Cash And Equivalents | 47.53 M | ||||
| Cash Per Share | 3.25 X | ||||
| Total Debt | 2.39 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 8.82 X | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (26.77 M) | ||||
| Short Ratio | 3.63 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Price To Earnings To Growth | (0.04) X | ||||
| Target Price | 10.33 | ||||
| Number Of Employees | 32 | ||||
| Beta | 1.63 | ||||
| Market Capitalization | 107.42 M | ||||
| Total Asset | 30.75 M | ||||
| Retained Earnings | (513.21 M) | ||||
| Working Capital | 19.67 M | ||||
| Current Asset | 134.26 M | ||||
| Current Liabilities | 12.63 M | ||||
| Net Asset | 30.75 M |
About Regulus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regulus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regulus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regulus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.